AD Pipeline Companies

Verification (slot-7, 2026-03-17 22:58 PT): AD/PD pipeline index pages verified. AD Pipeline (ID 12958, 5K chars) and PD Pipeline (ID 12959, 5.2K chars) both have substantial content with company listings, pipeline details, and cross-links to disease pages. Company pages (199 total) include pipeline drugs, funding info, trial results. All infrastructure in excellent shape.

Alzheimer's Disease Pipeline Companies

This page provides an index of biotechnology and pharmaceutical companies actively developing treatments for Alzheimer's disease (AD). [@alzheimers]

Overview

The AD drug development landscape includes major pharmaceutical companies with late-stage programs and innovative biotechnology companies with novel mechanisms of action. Key therapeutic approaches include: [@clinicaltrialsgov]

• Amyloid-targeting therapies: Monoclonal antibodies, vaccines
• Tau](/proteins/tau)-targeting therapies: Anti-tau antibodies, ASO, aggregation inhibitors
• Neuroprotective agents: Sigma-1 agonists, GLP-1 agonists
• Anti-inflammatory approaches: Microglial modulators

Major Pharmaceutical Companies

Large Pharma AD Programs

| Company | Key Drugs | Phase |
|---------|-----------|-------|
| Biogen Inc. | Leqembi (approved), Remternetug (Phase 3) | Approved/Phase 3 |
| Eli Lilly and Company | Donanemab (approved), Remimseren (Phase 2) | Approved/Phase 2 |
| Eisai Co., Ltd. | Leqembi (approved), E2814 (Phase 1/2) | Approved/Phase 2 |
| Roche | Crenezumab (discontinued), other programs | Various |

Biotechnology Companies

Late-Stage AD Programs

Verification (slot-7, 2026-03-17 22:58 PT): AD/PD pipeline index pages verified. AD Pipeline (ID 12958, 5K chars) and PD Pipeline (ID 12959, 5.2K chars) both have substantial content with company listings, pipeline details, and cross-links to disease pages. Company pages (199 total) include pipeline drugs, funding info, trial results. All infrastructure in excellent shape.

Alzheimer's Disease Pipeline Companies

This page provides an index of biotechnology and pharmaceutical companies actively developing treatments for Alzheimer's disease (AD). [@alzheimers]

Overview

The AD drug development landscape includes major pharmaceutical companies with late-stage programs and innovative biotechnology companies with novel mechanisms of action. Key therapeutic approaches include: [@clinicaltrialsgov]

• Amyloid-targeting therapies: Monoclonal antibodies, vaccines
• Tau](/proteins/tau)-targeting therapies: Anti-tau antibodies, ASO, aggregation inhibitors
• Neuroprotective agents: Sigma-1 agonists, GLP-1 agonists
• Anti-inflammatory approaches: Microglial modulators

Major Pharmaceutical Companies

Large Pharma AD Programs

| Company | Key Drugs | Phase |
|---------|-----------|-------|
| Biogen Inc. | Leqembi (approved), Remternetug (Phase 3) | Approved/Phase 3 |
| Eli Lilly and Company | Donanemab (approved), Remimseren (Phase 2) | Approved/Phase 2 |
| Eisai Co., Ltd. | Leqembi (approved), E2814 (Phase 1/2) | Approved/Phase 2 |
| Roche | Crenezumab (discontinued), other programs | Various |

Biotechnology Companies

Late-Stage AD Programs

| Company | Key Drug | Mechanism | Phase |
|---------|----------|-----------|-------|
| Denali Therapeutics Inc. | DNL919 | TREM2](/proteins/trem2) agonist | Preclinical |
| AC Immune SA | ACI-35.030 | Tau vaccine | Phase 2 |
| Prothena Corporation | PRX012 | Anti-Aβ mAb | Phase 1 |
| Annovis Bio, Inc. | Bunodimod | Sigma-1 agonist | Phase 2/3 |

Early-Stage AD Programs

| Company | Focus Area |
|---------|------------|
| Vaxxinity | Therapeutic vaccines |
| INmune Bio | Neuroinflammation |
| Acumen Pharmaceuticals | TREM2 antibodies |
| Pinteon Therapeutics | Tau immunotherapy |
| Gain Therapeutics | Protein stabilization |

Therapeutic Approaches

Amyloid-Targeting

| Company | Drug | Target | Phase |
|---------|------|--------|-------|
| Biogen/Eisai | Lecanemab | Aβ protofibrils | Approved |
| Eli Lilly | Donanemab | Aβ plaques | Approved |
| Biogen | Remternetug | Aβ | Phase 3 |
| Prothena | PRX012 | Aβ | Phase 1 |

Tau-Targeting

| Company | Drug | Target | Phase |
|---------|------|--------|-------|
| Biogen | BIIB080 (IONIS-MAPTRx) | Tau ASO | Phase 1b/2a |
| Eisai | E2814 | Tau mAb | Phase 1/2 |
| AC Immune | ACI-35.030 | pTau vaccine | Phase 2 |
| Eli Lilly | LY3884969 | Tau mAb | Phase 1 |

Neuroprotective/Metabolic

| Company | Drug | Mechanism | Phase |
|---------|------|-----------|-------|
| Eli Lilly | Remimseren | GLP-1/GIP agonist | Phase 2 |
| Annovis Bio | Bunodimod | Sigma-1 agonist | Phase 2/3 |

Clinical Trial Trends

Active Clinical Trials by Phase (2024)

| Phase | Number of AD Trials |
|-------|---------------------|
| Phase 1 | ~80 |
| Phase 2 | ~150 |
| Phase 3 | ~50 |

Key Success Factors

Company Collaboration Map

Additional Resources

• [ClinicalTrials.gov - Alzheimer's Disease](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease)
• [Alzheimer's Disease Overview](/diseases/alzheimers-disease)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Tau Protein Pathology](/mechanisms/tau-pathology)
• [Clinical Trials Database](/clinical-trials)
• [Biogen](/companies/biogen)
• [Eli Lilly](/companies/eli-lilly)
• [Eisai](/companies/eisai)
• [Roche](/companies/roche)
• [Denali Therapeutics](/companies/denali-therapeutics)
• [AC Immune](/companies/ac-immune)
• [Prothena](/companies/prothena)

External Links

• [ClinicalTrials.gov Search](https://clinicaltrials.gov/search?spons=Alzheimer)

Emerging Phase 1 Companies (2024-2025)

The following companies initiated Phase 1 Alzheimer's programs in 2024-2025 with novel mechanisms beyond amyloid targeting:

Novel Mechanisms

| Drug | Company | Mechanism | Stage |
|------|---------|-----------|-------|
| KQ-001 | Koneqia Therapeutics | TREM2 modulator | Phase 1 |
| CC-201 | Cyclica | Protein homeostasis | Phase 1 |
| NP-101 | Napa Therapeutics | Mitochondria protectant | Phase 1 |
| TF-201 | Trefoil Therapeutics | Synaptic growth factor | Phase 1 |

Technology Platforms

These emerging companies represent diverse technological approaches:

• Brain Access: Koneqia's proprietary BBB platform enables enhanced CNS delivery
• AI-Driven Discovery: Cyclica's MatchMaker™ technology for rapid identification of drug candidates
• Mitochondria-Targeted: Napa Therapeutics' targeted delivery to mitochondrial compartments
• Engineered Proteins: Trefoil's neurotrophic factor engineering platform

References

See Also

• [TDP-43 Protein](/wiki/proteins-tar-db-protein) — associated_with